Summary
We have cultured peripheral blood lymphocytes (PBL) from glioblastoma patients in recombinant interleukin-2 (IL-2) containing medium for a period of 5 days. The cytotoxicity of these cells was tested on 51Cr-labelled autologous dissociated glioblastoma cells which had not been cultured. Significant cytotoxicity against glioma cells was observed in seven out of nine cases. IL-2 activated PBL from normal donors were equally cytotoxic against these glioma cells. Autologous lymphocytes activated by phytohaemagglutinin were also lysed in most cases, and the erythroleukemia cell line K562 was highly susceptible to the cytotoxic capability of the IL-2 activated PBL. In cold target inhibition experiments, K562 inhibited the cytotoxicity against both autologous and allogenic glioma cells, and glioma cells inhibited the cytotoxicity against K562. Following immunomagnetic separation, the IL2 activated cells demonstrated cytotoxicity against glioma cells, K562 cells, and PHA blasts in both the CD8+ and the CD8− subsets.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313:1485–1492, 1985
Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2 activated lymphocytes. Annu Rev Immunol 4:681–709, 1986
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: In vitro killing of human glioblastoma by interleukin-2 activated autologous lymphocytes. J Neurosurg 64:114–117, 1986
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Ianterleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64:743–749, 1986
Miyatake S, Handa H, Yamashita J, Yamasaki T, Ueda M, Namba Y, Hanaoka M: Induction of human glioma-specific cytotoxic T -lymphocyte lines by autologous tumor stimulation and interleukin-2. J Neuro-Oncol 4:55–64, 1986
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841, 1982
Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine-activated killer cell phenomenon II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884–897, 1983
Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814–825, 1986
Ortaldo JR, Mason A, Overton R: Lymphokine activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193–1205, 1986
Hirschberg H, Skare H, Thorsby E: Cell mediated lympholysis: CML. A microplate technique requiring few target cells and employing a new method of supernatant collection. J Immunol Meth 16:131–141, 1977
Gaudernack G, Leivestad T, Ugelstad J, Thorsby E: Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres. J Immunol Meth 90:179–187, 1986
Leivestad T, Gaudernack G, Ugelstad J, Thorsby E: Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation. Tissue Antigens 28:46–52, 1986
Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41:4420–4425, 1981
Grimm EA, Wilson DJ: The human lymphokine activated killer cell system V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 94:568–578, 1985
Muul LM, Director EP, Hyatt CL, Rosenberg SA: Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Meth 88:265–275, 1986
Sondel PM, Hank JA, Kohler PC, Chen BP, Minkoff DZ, Molenda JA: Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 137:502–511, 1986
Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75:67–75, 1985
Allavena P, Ortaldo JR: Characteristics of human NK clones: Target specificity and phenotype. J Immunol 132:2363–2369, 1984
Hercend T, Reinherz EL, Meuer S, Schlossman SF, Ritz J: Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature 301:158–160, 1983
Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495–507, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bosnes, V., Hirschberg, H. Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro . J Neuro-Oncol 6, 85–92 (1988). https://doi.org/10.1007/BF00163545
Issue Date:
DOI: https://doi.org/10.1007/BF00163545